

## THERAPEUTIC EFFECTS OF HYDROALCOHOLIC AND AQUEOUS EXTRACTS OF BERBERIS VULGARIS FRUITS IN STREPTOZOTOCIN INDUCED TYPE 1 DIABETES MELLITUS RATS

Masoumeh Karami<sup>1</sup>, Masood Sepehrimanesh<sup>2,✉</sup>, Omid Koohi-Hosseinabadi<sup>3</sup>,  
Mohammadreza Fattahi<sup>1</sup>, Iman Razeghian Jahromi<sup>4</sup>, Maral Mokhtari<sup>5</sup>,  
Maryam Vasheghani Farahani<sup>6</sup>

<sup>1</sup> Department of Biochemistry, School of Medicine, AJA University of Medical Sciences, Tehran, Iran

<sup>2</sup> Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>3</sup> Center of Comparative and Experimental Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>4</sup> Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>5</sup> Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>6</sup> Department of Forensic Medicine, AJA University of Medical Sciences, Tehran, Iran

received:

May 22, 2016

accepted:

August 11, 2016

available online:

September 15, 2016

### Abstract

**Background and Aims:** To evaluate and compare the beneficial effects of aqueous and hydroalcoholic extracts of *Berberis vulgaris* fruit in streptozotocin (STZ) induced type 1 diabetes mellitus (DM). **Materials and Methods:** Forty male rats were allocated into 4 groups as negative control (NC), positive control (PC), aqueous extract (AE), and hydroalcoholic extract (HE). DM was induced with streptozotocin (STZ) and three days later, the AE and HE groups received 200 mg/kg extracts orally for 30 days. The serum liver enzymes plus glucose level and concentration of HbA1c three days after STZ injection and at day 30 and liver histopathology at the end of the study were analyzed. **Results:** PC and both treatments groups had higher serum glucose levels in comparison to NC group ( $P < 0.05$ ). Higher serum alanine aminotransferase activities in both AE and HE groups in comparison to PC group ( $P = 0.005$  and  $P = 0.045$ , respectively) and lower percentage of HbA1c in NC and HE groups in comparison to PC group ( $P = 0.001$  and  $P = 0.014$ , respectively) were detected. **Conclusion:** Noticing the beneficial effects of *B. vulgaris*, the extract of this plant can be a good choice attenuating the side effects of DM.

**key words:** Diabetes mellitus, *Berberis vulgaris*, aminotransferase, histopathology.

### Background and Aims

Diabetes mellitus (DM) is a metabolic disease characterized by high blood sugar levels over a prolonged period. This is the most

common endocrine disease, resulting from defects in insulin secretion, action or both. International Diabetes Federation in 2015 indicated a diabetes prevalence of approximately 9%, with a total of near 415 million diabetic

✉ Tel/fax: +98-71-36281442;  
corresponding author e-mail: sepehrimaneshmasood@gmail.com

subjects worldwide. [1]. Long term DM is accompanied by serious complications such as cardiovascular disorders and renal, neuropathic and eye related diseases which cause early disability and death. Also, the quality of life is severely affected in this disease and imposes health care costs to individuals and society [2]. Pattern of global incidence and prevalence of diabetes mellitus shows that the disease is more frequent in developing countries and in the low socio-cultural peoples of developed countries [2]. Therefore, applying prevention and therapeutic strategies in these groups are highly needed.

In recent years, use of traditional medicinal plant and their derivatives as replacement or supplementary treatments in different diseases in human and animal models received more attention by scientists [3-8]. *Berberis vulgaris* (simply called Barberry), is a plant in the family of Berberidaceae. The genus of *Berberis* contains about 500 species worldwide but 3 of them (*B. orthobotrys*, *B. khorassanica*, and *B. vulgaris*) are mainly found and cultured in northern, eastern and south-east of Iran. The South Khorasan province is the world's largest barberry cultivation area [9]. Several therapeutic effects such as antihistaminic, anticholinergic and anti-inflammatory were reported for *B. vulgaris* [10]. Such effects are related to its contents include berberine, berbamine, alkaloids, tannins and polyphenolic antioxidants [11]. The number of studies about the beneficial effects of *B. vulgaris* in treatment of DM is scarce. For instance, Taheri and colleagues in 2012 reported that hydroalcoholic extract of root of *B. vulgaris* compensated the hypercholesterolemia related elevation of liver enzymes due to its antioxidant contents [12]. Also, Shidfar and collaborators found that hydroalcoholic extract of *B. vulgaris* could normalize serum lipoproteins, apoB, and apoA-I in type 2 diabetic patients [13].

We previously reported the beneficial therapeutic effects of some medicinal plants in experimental DM models [3,4,7]. There are no reports about the effects of hydroalcoholic and aqueous extracts of *B. vulgaris* fruits in type 1 DM. Therefore, we focused on the evaluation of liver transferase enzymes and liver histopathology as well as blood hemoglobin A1c (HbA1c) and serum glucose level in male rats with DM induced by streptozotocin (STZ).

## Materials and Methods

### *Ethics statement*

This study was undertaken at the Center of Comparative and Experimental Medicine and was approved by the Ethical Committee of Shiraz University of Medical Sciences, Shiraz, Iran and AJA University of Medical Sciences, Tehran, Iran. All efforts were made to minimize suffering during the experimental period. Also, we included the lowest number of animals per each group in order to receive approval from animal welfare but still reach statistical significances.

### *Animals*

Forty male adult Sprague Dawley rats ( $180 \pm 10$  g) were obtained from the Center of Comparative and Experimental Medicine, Shiraz University of Medical Sciences. The animals were housed in standard cages, 5 rats per cage, and maintained in experimental conditions (12-h light/dark cycles, temperature of  $22 \pm 2$  °C, and 50% relative humidity), with free access to food and water. Rats were left undisturbed to acclimatize for 3 days before the experiments.

### *Plant materials and extracts preparation*

*B. vulgaris* fresh fruits were purchased from local market. These fruits were harvested from Birjand, South Khorasan, Iran (GPS coordinates: Latitude: 32.864904 | Longitude: 59.226247).

Taxonomic identification of the plant material was confirmed by the local research laboratory and also matched to the digital herbarium of Botanical Garden and Botanical Museum Berlin-Dahlem, Freie University, Berlin (<http://herbarium.bgbm.org/object/BW06922010>). The fruits were checked for any fungal contaminations, washed carefully with warm water and then were air-dried at room temperature in the shade for three years. The fruits were grounded to a fine powder and were used for preparation of hydroalcoholic and aqueous extracts based on protocols which reported previously [4,6]. Both extracts were then stored at 4 °C until use for gavage administration.

#### *Interventions*

In a double-blind animal-based controlled randomized clinical trial, rats were randomly allocated into four equal independent groups. The feed treatments were applied to each group as follow:

Group 1 (negative control, NC): Neither DM induction, nor treatments

Group 2 (positive control, PC): DM induction without treatments.

Group 3 (aqueous extract, AE): DM induction and dietary treatment with 200 mg/kg aqueous extract for 30 consecutive days.

Group 4 (hydroalcoholic extract, HE): DM induction and dietary treatment with 200 mg/kg hydroalcoholic extract for 30 consecutive days.

DM was induced by administration of 60 mg/kg STZ, intraperitoneally, after 24 h off feeding. Treatments were applied using gavage needle at the 8.00 AM of each day by an expert technician who was familiar with animal working. Also, the two control groups received similar volumes of normal saline.

#### *Biochemical measurements*

Blood sampling was performed at 3 days after DM induction (as day 0) and at the end of

the study (day 30). The serum activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) plus glucose level were measured by autoanalyzer BT-3000 (Biotechnica Instruments, Italy) using commercial kits and reagents (ParsAzmoon Co, Iran). The concentration of HbA1c was evaluated using high performance liquid chromatography (HPLC) by ion exchange column.

#### *Pathological evaluations*

At the end of the experiment, the animals were anesthetized with ether and at deep anesthesia were killed by cervical dislocation. The liver was immediately removed and fixed in 10 % buffered formalin for histopathologic examination. Formalin-fixed tissues were processed routinely and embedded in paraffin. Blocks were cut at 5 µm sections and then were stained with hematoxylin-eosin. All sections were studied and photographed by a light photomicroscope [14].

#### *Statistical analysis*

All data were expressed as mean and SD and analyzed using SPSS version 21. The between group comparison was performed using one way analysis of variance (ANOVA). The Tukey test was used as Post hoc test. P value lower than 0.05 was considered as significant difference.

#### **Results**

The mean and SD of serum activity of liver enzymes and glucose levels plus percentage of HbA1c in the beginning of the study (day 3) and at the end of the study (day 30) are presented in [Table 1](#). As presented, only the serum glucose level was affected in related to DM and positive control and both treatments groups had higher serum glucose levels in comparison to negative control group at day 3 (P<0.05). At the end of

the study, only significant differences were detected in ALT activity and percentage of HbA1c. These include higher serum ALT activities in both aqueous and hydroalcoholic extract groups in comparison to positive control

group (P=0.005 and P=0.045, respectively) and lower percentage of HbA1c in negative control and hydroalcoholic extract groups in comparison to positive control group (P=0.001 and P=0.014, respectively).

**Table 1.** Comparison of mean and standard deviation (SD) of serum activity of liver enzymes and glucose concentration plus percentage of HbA1c at the beginning of the study (day 3) and in the end of the study (day 30).

Groups	Liver enzymes activity (IU/L)				Blood glucose	HbA1c
	ALT	AST	ALP	GGT	(mg/dl)	(%)
Day 3						
NC	37.30±2.18 <sup>a</sup>	3.30±0.30 <sup>a</sup>	2469.70±84.41 <sup>a</sup>	3.68±0.33 <sup>a</sup>	416.70±66.08 <sup>a</sup>	4.09±0.17 <sup>a</sup>
PC	36.80±3.18 <sup>a</sup>	3.60±0.48 <sup>a</sup>	2459.10±91.11 <sup>a</sup>	2.91±0.57 <sup>a</sup>	788.60±37.66 <sup>b</sup>	4.24±0.19 <sup>a</sup>
AE	45.70±3.05 <sup>a</sup>	3.10±0.18 <sup>a</sup>	2810.60±235.11 <sup>a</sup>	2.84±0.75 <sup>a</sup>	688.30±29.57 <sup>b</sup>	4.25±0.10 <sup>a</sup>
HE	41.40±2.88 <sup>a</sup>	4.70±0.82 <sup>a</sup>	2777.60±364.41 <sup>a</sup>	3.09±0.38 <sup>a</sup>	738.50±29.95 <sup>b</sup>	4.36±0.14 <sup>a</sup>
Day 30						
NC	36.60±9.00 <sup>AB</sup>	5.20±1.74 <sup>A</sup>	2179.40±491.68 <sup>A</sup>	2.29±1.08 <sup>A</sup>	535.60±92.71 <sup>A</sup>	4.10±0.18 <sup>A</sup>
PC	19.22±8.20 <sup>B</sup>	4.11±1.45 <sup>A</sup>	3057.22±650.91 <sup>A</sup>	3.77±2.07 <sup>A</sup>	630.11±122.08 <sup>A</sup>	8.05±0.87 <sup>B</sup>
AE	60.00±6.81 <sup>A</sup>	3.10±1.51 <sup>A</sup>	2181.00±499.69 <sup>A</sup>	1.88±0.92 <sup>A</sup>	425.70±94.74 <sup>A</sup>	6.12±0.75 <sup>AB</sup>
HE	50.00±7.16 <sup>A</sup>	6.70±1.89 <sup>A</sup>	2169.60±514.17 <sup>A</sup>	2.68±0.83 <sup>A</sup>	476.30±99.19 <sup>A</sup>	5.07±0.61 <sup>A</sup>

NC, negative control; PC, positive control; AE, aqueous extract; HE, hydroalcoholic extract. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase. Significant differences in each factor indicated by different superscript lower and upper case letter in each column for day 3 and 30, respectively.

Histopathological features of the liver in the different groups are presented in [Figure 1](#). The histopathological evaluations demonstrated that several lesions exist in the liver based on the grouping. These include lack of any pathological changes in NC, hepatocytes confluent necrosis and massive necrosis with abscess formation in PC group ([Figure 1A](#)), mild portal inflammation, mild and focal spotty necrosis and granuloma formation in AE group ([Figure 1B](#)), mild portal inflammation and mild and focal spotty necrosis in HE group ([Figure 1C](#)). As shown, the severity and extent of the lesions were higher in PC group than AE group and in AE group than HE group.


## Discussion

In the present study, the therapeutic effects of 30 days oral consumption of aqueous and hydroalcoholic extract of *B. vulgaris* in STZ induced type 1 DM male rats were evaluated

using measurement of liver histopathology, serum hepatic enzymes activity and glucose concentration plus blood HbA1c percentage. Totally, we found that both extracts, especially hydroalcoholic form, prevented severe DM related hepatic injuries, and decreased the percentage of HbA1c.

Use of traditional medicinal plants has obtained great interest by scientists. In this study, administration of STZ to rats resulted in hyperglycemia as expected. Indeed, STZ is absorbed by pancreatic  $\beta$  cells and induced cell death in them by alkylation of DNA, production of nitric oxide (NO) and reactive oxygen species (ROS) [15]. Therefore, STZ inhibits insulin secretion and elevate the serum glucose level. It has been reported that *B. vulgaris* contains an effective alkaloid, berberine, that shows antidiabetic effects. This is an organic cation that penetrates cell membrane and binds to DNA molecule [16], and induces DNA conformational

changes and alters gene expression [17]. In some of the previous studies, the hypoglycemic or anti-hyperglycemic effects of some species of Berberis such as *B. aristata* [18], *B. lyceum* [19], *B. integerrima* [20], and *B. vulgaris* [13,21,22] were reported.



**Figure 1.** Histopathological changes of the liver. A, massive necrosis and abscess formation in PC group (H&E, ×100); B, inflammatory cell infiltration of a portal tract with granuloma formation AE group (H&E, ×250); C, necrosis of hepatocytes with acute and chronic

*inflammatory cells infiltration in HE group (H&E, ×400). The related lesions indicated by black arrows.*

*B. vulgaris* contains several alkaloids and effective substances that were reviewed by Mokhber-Dezfouli and colleagues [9]. Among them, berberin is better known for its therapeutic effects. There are some reports which express the beneficial effects of berberine on the liver functions, bile secretion and lowering serum low density lipoprotein (LDL) concentration [23]. Berberine can act similar to metformin in reducing serum glucose level by aldolase reductase inhibition, glycolysis induction, and prevention of insulin resistance through enhancing of insulin receptor expression [23,24]. Also, berberine decrease the serum blood glucose due to protein kinase B activation and increasing of glucose uptake due to 5' AMP-activated protein kinase (AMPK)-38 molecular pathway [19]. It seems that the beneficial effects for *B. vulgaris* aqueous and hydroalcoholic extracts in lowering serum glucose level and HbA1c percentage described in our experiment are related to the berberin content of this plant.

Our findings about the hypoglycemic effects of aqueous and hydroalcoholic extracts of *B. vulgaris* are in line with those found by Hemmati and collaborator [25], but opposite with those found by Hajzadeh et al [26]. Hajzadeh and colleagues reported that the aqueous extract of *B. vulgaris* fruit at amounts of 3.5 and 7.5% of drinking water did not possess hypoglycemic and hypolipidemic activity in STZ-diabetic rats during 6-week treatment period [26]. The main reasons for this discrepancy is the lower dose of the plant extract in comparison to our dose and also use of only aqueous extract against the hydroalcoholic extract which we used. Shidfar et al in 2012 reported that the intake of 3 g per day of aqueous extract of *B. vulgaris* for 3 months may have beneficial effects on glycemic control in type 2 diabetic patients. They found no

significant effects on the percentage of HbA1c but found significant decline in the serum glucose level [13]. About the hepatic effects of this plant, Taheri and colleagues reported that hydroalcoholic extract of root of *B. vulgaris* in hyperlipidemic rat can significantly reduce the serum activities of ALT and ALP, without any changes in serum AST activity [12]. Preventive effects of aqueous extract of *B. integerrima* root on liver injury in type 1 DM rats were evaluated by Ashraf and Zare in 2015. They reported that administration of aqueous extract of *B. integerrima* root before diabetes induction resulted in enhanced amelioration of liver complications compared to the group receiving it after induction, indicating that it can play a preventive role in this animal model [20]. Their results are in line with our findings except in lack of any changes in the serum activity of AST and ALP which can be related to difference in the time and dose of the administration. Despite of our findings, this study suffered from two limitations. These include no measurement of serum insulin level and lack of histopathological changes of the pancreas.

## Conclusion

The present study demonstrated that consumption of aqueous and hydroalcoholic extracts of *B. vulgaris* for 30 consecutive days as dose of 200 mg/kg can beneficially affect the hepatic liver enzymes, especially ALT, due to the liver regeneration and providing the source of the liver enzyme. Also, these extracts beneficially impact liver histopathology and percentage of HbA1c. Performing other research to overcome the limitations of this study and also performing molecular evaluation of results which we found in this study are highly recommended in the future.

## Acknowledgment and Duality of interest.

Authors wish to thanks the staff of Gastroenterohepatology Research Center and Pathology Department of Shiraz University of Medical Science, Shiraz, Iran for their kindly scientific helps. Authors declared that there are no conflict of interests.

## REFERENCES

---

1. **International Diabetes Federation** (2015) <http://www.diabetesatlas.org/>.
2. **Matthews DR.** Diabetes mellitus: A fundamental and clinical text. *Clin Endocrinol* 53: 543-544, 2000.
3. **Hafezi H, Vahdati A, Sepehrimanesh M.** Effect of *Satureja khuzestanica* Jamzad extract on serum lipid profile, blood glucose level and body weight gain in diabetes mellitus: a *Rattus norvegicus* model. *Comp Clin Pathol* 24: 1033-1037, 2015.
4. **Koochi-Hosseiniabadi O, Moini M, Safarpour A et al.** Effects of dietary *Thymus vulgaris* extract alone or with atorvastatin on the liver, kidney, heart, and brain histopathological features in diabetic and hyperlipidemic male rats. *Comp Clin Pathol* 24: 1311-1315, 2015.
5. **Nazifi S, Saeb M, Sepehrimanesh M et al.** The effects of wild pistachio oil on serum leptin, thyroid hormones, and lipid profile in female rats with experimental hypothyroidism. *Comp Clin Pathol* 21: 851-857, 2012.
6. **Safarpour AR, Kaviyani F, Sepehrimanesh M et al.** Antioxidant and anti-inflammatory effects of gel and aqueous extract of *Melilotus officinalis* L. in induced ulcerative colitis: A *Rattus norvegicus* model. *Annals Colorectal Res* 3: e29511, 2015.
7. **Shojaee SS, Vahdati A, Assaei R et al.** Effect of *Galega officinalis* leaf powder and *Trigonella foenum-graecum* seed powder on blood glucose levels and weight gain in a diabetes mellitus rat model. *Comp Clin Pathol* 24: 145-148, 2015.
8. **Yazdani A, Poorbaghi SL, Habibi H et al.** Dietary *Berberis vulgaris* extract enhances intestinal mucosa morphology in the broiler chicken (*Gallus gallus*). *Comp Clin Pathol* 22: 611-615, 2013.

9. **Mokhber-Dezfuli N, Saeidnia S, Gohari AR et al.** Phytochemistry and pharmacology of berberis species. *Pharmacog Rev* 8: 8-15, 2014.
10. **Akbulut M, Calisir S, Marakoglu T et al.** Some physicochemical and nutritional properties of barberry (*Berberis vulgaris* L.) fruits. *J Food Process Engin* 32: 497-511, 2009.
11. **Rounsaville TJ, Ranney TG.** Ploidy levels and genome sizes of *Berberis* L. and *Mahonia* Nutt. species, hybrids, and cultivars. *Hort Sci* 45: 1029-1033, 2010.
12. **Taheri S, Zarei A, Changizi Ashtiyani S et al.** Evaluation of the effects of hydroalcoholic extract of *Berberis vulgaris* root on the activity of liver enzymes in male hypercholesterolemic rats. *Avicenna J Phytomed* 2: 153-161, 2012.
13. **Shidfar F, Seyyed Ebrahimi S, Hosseini S, et al.** The effects of *Berberis vulgaris* fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients. *Iranian J Pharmaceut Res* 11: 643-652, 2012.
14. **Panahi M, Karimaghai N, Rahmanifar F et al.** Stereological evaluation of testes in busulfan-induced infertility of hamster. *Comp Clin Pathol* 24: 1051-1056, 2015.
15. **Szkudelski T.** The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. *Physiol Res* 50: 537-546, 2001.
16. **Zarei A, Changizi Ashtiyani S, Taheri S et al.** A quick overview on some aspects of endocrinological and therapeutic effects of *Berberis vulgaris* L. *Avicenna J Phytomed* 5: 485-497, 2015.
17. **Yin J, Xing H, Ye J.** Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism* 57: 712-717, 2008.
18. **Upwar N, Patel R, Waseem N et al.** Hypoglycemic effect of methanolic extract of *Berberis aristata* DC stem on normal and streptozotocin induced diabetic rats. *Int J Pharm Pharmaceut Sci* 3: 222-224, 2011.
19. **Gulfraz M, Arshad M, Nayyer N et al.** Investigation for bioactive compounds of *Berberis Lyceum* royle and *Justicia adhatoda* L. *Ethnobotan Leaflets* 2004: 51-62, 2004.
20. **Ashraf H, Zare S.** Preventive effects of aqueous extract of *Berberis integerrima* bge. root on liver injury induced by diabetes mellitus (type 1) in rats. *Iranian J Pharmaceut Res* 14: 335-343, 2015.
21. **El-Wahab AEA, Ghareeb DA, Sarhan EEM et al.** In vitro biological assessment of *Berberis vulgaris* and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. *BMC Complement Alternat Med* 13: 218, 2013.
22. **Meliani N, Dib MEA, Allali H, Tabti B.** Hypoglycaemic effect of *Berberis vulgaris* L. in normal and streptozotocin-induced diabetic rats. *Asian Pacific J Tropic Biomed* 1: 468-471, 2011.
23. **Yin J, Gao Z, Liu D et al.** Berberine improves glucose metabolism through induction of glycolysis. *Am J Physiol Endocrinol Metabol* 294: 148-156, 2008.
24. **Lou T, Zhang Z, Xi Z et al.** Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. *Inflammation* 34: 659-667, 2011.
25. **Hemmati M, Asghari S, Zohoori E.** Effects of alcoholic and aqueous extract of barberry, jujube and saffron petals on serum level of adiponectin and lipid profile in diabetic rats. *Iranian J Endocrinol Metabol* 16: 329-337, 2015.
26. **Hajzadeh MAR, Rajaei Z, Shafiee S et al.** Effect of barberry fruit (*Berberis vulgaris*) o serum glucose ad lipids in streptozotocin-diabetic rats. *Pharmacol Online* 1: 809-17, 2011.